In recent studies, various clinical trials have examined the effectiveness of CAR T-cell therapy for GBM by targeting epidermal growth factor receptor variant III (EGFRvIII), interleukin (IL)13Rα2 (IL-13Ra2), and ephrin-A2 (HER2). The gene discussed is IL13RA2; the disease is glioblastoma.